

Table 1 Patient characteristics

	HFrEF (n = 46)	HFpEF (n = 42)	p-value
Age; years	67±14	69±11	0.505
Male gender; n (%)	34 (74)	30 (71)	0.794
BMI; kg/m ²	23±4	24±3	0.452
NYHA class; n (%)			0.008
I	22 (48)	31 (74)	
II	17 (37)	11 (26)	
III	7 (15)	0 (0)	
Underlying disease; n (%)			0.321
IHD	31 (67)	24 (57)	
non-IHD	15 (33)	18 (43)	
IHD profile; n (% of IHD)			
multi-vessel disease; n (%)	19 (61)	14 (58)	0.824
PCI; n (%)	24 (77)	17 (71)	0.578
CABG; n (%)	9 (29)	7 (29)	0.991
Comorbidities; n (%)			
Hypertension	18 (39)	21 (50)	0.305
Diabetes	18 (39)	16 (38)	0.921
Dyslipidemia	21 (46)	15 (36)	0.344
Stroke	5 (11)	2 (5)	0.290
Chronic kidney disease	27 (59)	20 (48)	0.298
Smoking	33 (72)	23 (55)	0.098
Medications; n (%)			
ACE inhibitors/ARBs	29 (63)	29 (69)	0.553
Beta blockers	31 (67)	10 (24)	<0.0001
Aldosterone antagonists	27 (59)	7 (17)	<0.0001
Loop diuretics	38 (83)	19 (45)	0.0002
Statins	32 (70)	29 (69)	0.958
Anti-diabetic drugs	16 (35)	14 (33)	0.886

HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; BMI, body mass index; NYHA, New York Heart Association; IHD, ischemic heart disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; ACE, angiotensin converting enzyme; ARBs, angiotensin receptor blockers